We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+26.6%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$127M
AUM Growth
+$23.1M
Cap. Flow
+$11.3M
Cap. Flow %
8.85%
Top 10 Hldgs %
92.09%
Holding
19
New
2
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$11.1M
2
LQDA icon
Liquidia Corp
LQDA
+$4.18M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$2.43M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$2.75M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.56M
3
KALV
KalVista Pharmaceuticals
KALV
+$683K
4
ALLK
Allakos
ALLK
+$463K
5
PDSB icon
PDS Biotechnology
PDSB
+$8

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$23.6M 18.54%
210,937
-23,438
-10% -$2.56M
ALLK
2
DELISTED
Allakos
ALLK
$18.1M 14.22%
446,905
-11,461
-3% -$463K
ODT
3
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$13.2M 10.35%
595,850
– –
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$13M 10.25%
383,480
– –
STRO icon
5
Sutro Biopharma
STRO
$379M
$12.8M 10.08%
112,558
– –
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$11.5M 9.08%
+532,920
New +$11.1M
SYRS
7
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.69M 7.61%
105,994
– –
LQDA icon
8
Liquidia Corp
LQDA
$7.67B
$7.28M 5.72%
639,290
+260,870
+69% +$4.18M
VIRX
9
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.56M 3.58%
+107,143
New +$2.43M
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$3.39M 2.66%
118,500
-31,500
-21% -$683K
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.12M 2.45%
442,733
– –
ATXS
12
DELISTED
Astria Therapeutics
ATXS
$2.38M 1.87%
50,000
– –
EVLO
13
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$1.82M 1.43%
11,376
– –
UROV
14
DELISTED
Urovant Sciences Ltd.
UROV
$1.58M 1.24%
157,480
– –
TPST icon
15
Tempest Therapeutics
TPST
$14.8M
$677K 0.53%
231
– –
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$373K 0.29%
78,300
– –
PDSB icon
17
PDS Biotechnology
PDSB
$38.1M
$68K 0.05%
9,166
-1
-0% -$8
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
$47K 0.04%
71,619
– –
VRDN icon
19
Viridian Therapeutics
VRDN
$2.13B
– –
-60,606
Closed -$2.75M

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q1 2019 Portfolio in Review

As of Q1 2019, Samsara BioCapital held 19 positions worth $127M, up 22% from $104M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Samsara BioCapital deployed $11.3M of net new capital in Q1 2019, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Gossamer Bio: 532,920 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Intercept Pharmaceuticals, Inc., an estimated $2.56M trimmed.

  • Samsara BioCapital's largest Q1 2019 buy was Gossamer Bio: 532,920 shares worth $11.5M.
  • Samsara BioCapital added most to Liquidia Corp in Q1 2019, an estimated $4.18M increase.
  • Samsara BioCapital's biggest Q1 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $2.56M.
  • Samsara BioCapital fully exited Viridian Therapeutics in Q1 2019, selling an estimated $2.75M.
  • Samsara BioCapital's ten largest holdings make up 92% of its $127M portfolio in Q1 2019.
  • Samsara BioCapital opened 2 new positions and closed 1 in Q1 2019.
  • Samsara BioCapital's portfolio value rose 22% quarter-over-quarter to $127M.

Based on Samsara BioCapital's 13F filing for Q1 2019, filed 15 May 2019.